Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q1 FY20 results · Apr–Jun 2019
Astec LifeSciences reported revenue from operations of ₹76.99 crore (up 17.6% from Q1 FY19) and net loss of ₹1.11 crore for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 76.99 | 65.47 | +17.6% | 133.76 | −42.4% |
| Other income | 0.94 | 0.02 | 52x | 5.76 | −83.7% |
| Total income | 77.93 | 65.49 | +19.0% | 139.52 | −44.1% |
| Profit before tax | (1.72) | 2.45 | Turned loss | 20.22 | Turned loss |
| Net profit for the period | (1.11) | 1.49 | Turned loss | 12.73 | Turned loss |
| EPS, basic (₹) | (0.57) | 0.08 | Turned loss | 6.50 | Turned loss |
| Net margin (%) | -1.4 | 2.3 | 9.5 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 76.99 | 65.47 | +17.6% | 133.76 | −42.4% |
| Other income | 0.94 | 0.02 | 52x | 5.74 | −83.6% |
| Total income | 77.93 | 65.49 | +19.0% | 139.50 | −44.1% |
| Profit before tax | (1.74) | 2.43 | Turned loss | 20.18 | Turned loss |
| Net profit for the period | (1.12) | 1.48 | Turned loss | 12.70 | Turned loss |
| EPS, basic (₹) | (0.57) | 0.08 | Turned loss | 6.50 | Turned loss |
| Net margin (%) | -1.5 | 2.3 | 9.5 |
Consolidated
- Filed with BSE
- 27 Jul 2019, 12:12 IST
- Board meeting
- 26 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2019, 12:12 IST
- Board meeting
- 26 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE